Human PCSK9 Protein, Recombinant
產(chǎn)品貨號：PR00455HuM1
$ 詢價
規(guī)格 100ug
產(chǎn)品名稱：Human PCSK9 Protein, Recombinant
純度：≥95 % as determined by SDS-PAGE
內(nèi)毒素：< 1.0 EU per μg of the protein as determined by the LAL method
生物活性：/
序列起止：Met1~Gln692
標簽：N-His tag
Uniprot鏈接：Q8NBP7
表達系統(tǒng)：293F
種屬：Human
預(yù)測 N 端：Met
預(yù)測分子量：74.3
緩沖液：20mM Tris, 250mM imidazole, 500mM NaCl, pH8.0, containing 10% glycerol.
運輸方式：This Protein is shipped as lyophilized powder at ambient temperature. Upon receipt, store it immediately at the temperature recommended.
穩(wěn)定性 & 儲存條件：Store for up to one year at -20°C to -80°C as lyophilized powder.
復(fù)溶：Please refer to COA for detailed information
質(zhì)量驗證圖：/
別稱：Narc1
背景信息：Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial protein governing the circulating levels of low density lipoprotein-cholesterol (LDL-C), by virtue of its pivotal role in the degradation of the LDL receptor (LDLR). PCSK9 is expressed in the kidney and lung. It is synthesized as a 72 kDa immature precursor that undergoes autocatalytic cleavage in the endoplasmic reticulum to generate a 63 kDa mature protein. The cleaved N-terminal fragment remains associated with the mature protein and is necessary for its secretion, allowing it to circulate in the blood. The ability of PCSK9 to regulate a diverse group of cell-surface proteins hinted that it might also be able to influence additional membrane proteins that are important in anti-tumour immune responses. Targeting PCSK9 to treat cancer is also attractive because two neutralizing antibodies against it, evolocumab and alirocumab, have already been approved for human clinical use to lower cholesterol levels. (PMID: 30522786, PMID: 22493497)
全稱：Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
說明書：待上傳